We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · October 26, 2021

Impact of Cisplatin on Renal Function and Local Control Rate in Patients With Muscle-Invasive Bladder Cancer

Clinical Genitourinary Cancer


Additional Info

Clinical Genitourinary Cancer
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial
Clin Genitourin Cancer 2021 Sep 08;[EPub Ahead of Print], S Culine, V Harter, G Gravis, A Fléchon, C Chevreau, H Mahammedi, B Laguerre, A Guillot, F Joly, S Abadie-Lacourtoisie, L Geoffrois, FD Fiore, G Roubaud, P Barthélémy, E Voog, S Emambux, C Serrate, C Saldana, T Nguyen-Tan-Hon, Y Loriot, JC Eymard, O Huillard, F Rolland, N Houédé, JP Spano, ME Demery, S Vieillot, T L'Haridon, W Hilgers, Y Allory, C Pfister

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading